2. SARC Initially the North American Consortium of CTOS 501.c.3 organization Incorporated November 2003

3. SARC Mission and Vision Collaborate to design clinical trials Further the knowledge regarding diagnosis and treatment of sarcoma Provide information to physicians, patients and families Utilize state of the art statistical design Engage all appropriate and necessary resources to cure and prevent sarcomas

4. Statistical Center Operations L. Baker D. Reinke SARC CTOS Institution – Multiple members of CTOS Board of Directors – Majority from CTOS SARC

5. Board of Directors Officers President Vice President Secretary Treasurer Executive Committee Officers Chairpersons of standing committees Operations Office Statistical Center

6. SARC Executive Committee L. Baker, Executive Director B. Maki, Deputy Executive Director G. Demetri S. Patel B. Benjamin (consultant) L. Helman (consultant)

7. SARC Participants Participant Committee –B. Maki, Chair –P. Meyers –S. George

8. SARC Participants –Sant Chawla, MD Century City Hospital –Arthur Staddon, MD Pennsylvania Oncology –Martin Blackstein, MD University of Toronto –Amir Shahlaee, MD University of Florida –William Tapp, MD UCLA –Dennis Priebat, MD Washington Cancer Institute –Chris Ryan, MD Oregon Health Science –Meg Von Mehren, MD Fox Chase –Kenneth Hande, MD Vanderbilt –James Butrynski, MD University of Washington - Robert Benjamin, MD MDAnderson Cancer Center -Robert Maki, MD, PhD MSKCC -Scott Schuetze, MD. PhD University of Michigan -Lee Helman, MD NCI-Pediatric Branch -Gina D’Amato, MD Moffitt Cancer Center -Michael Fanucchi, MD Emory -George Demetri, MD Dana Farber -David Harmon, MD Massachusetts General -Scott Okuno, MD Mayo Clinic

9. Pending Participants Charles Forscher –Cedar Sinai Charlotte Jacobs –Stanford Tom Budd –Cleveland Clinic Foundation Daniel Rushing –Indiana University Warren Chow –City of Hope David Ettinger –Johns Hopkins Alberto Pappo –Texas Children’s

10. European Collaborators Denmark The Netherlands Belgium Germany Hungary Switzerland Slovakia Poland Italy France Spain UK Serbia Norway Sweden

11. Common features of studies Multi-center –Pediatric and medical oncology “Novel agents” and / or novel design Multiple subtypes of sarcoma permitted –Specific arms for several subtypes Biological correlates key component of studies Strong biostatistical input on all studies Web-based patient registration and evaluation

12. SARC Trials SARC001 Gleevec in multiple subtypes SARC002 G v GT in metastatic STS SARC003 GT in bone tumors SARC004 Preop Gleevec in DFSP SARC005 Adjuvant therapy in high-risk uterine leiomyosarcoma SARC006 Sporadic vs nf1 MPNST SARC007 Perifosine in chemoresistant sarcoma SARC008 SMART Trial SARC009 Dasatinib in selected subtypes of sarcoma SARC010 Dasatinib in GIST SARC011 Lilly compound

13. SARC Developmental Therapeutics SUBCOMMITTEE CHAIR Peter Houghton PRECLINICAL LABS –Experimental Therapeutics Lee Helman Larry Baker –INVIVO: Peter Houghton( STS) Rich Gorlick (OSTEOSARC) Chand Khana (dogs) CLINICAL TRIALS –PHASE I Tony Tolcher

14. SARC Funding Sources US Government –DOD –DOE Philanthropy Pharma

15. SARC Vision Build upon strengths of sarcoma programsBuild upon strengths of sarcoma programs Expand the ability to move quickly with efficient coordinationExpand the ability to move quickly with efficient coordination Develop infrastructure to facilitate collaborationDevelop infrastructure to facilitate collaboration Improve options for treatment and cure of sarcomaImprove options for treatment and cure of sarcoma

16. Chawla-Rosenfeld Developmental Therapeutics Symposia